Ayizo Biologics Recalls Its Viable Bone Matrix Products
Company recalls product after two patients develop M. tuberculosis
Last Thursday, Ayizo Biologics announced a voluntary recall of its viable bone matrix products. The recall followed reports of two Mycobacterium tuberculosis infections from a single donor lot. The company says it has suspended shipments of all viable bone matrix products from all donor lots, that the FDA and CDC are looking into the events in question, and that the company is working with the CDC to notify physicians of the patients who received product from the donor lot at issue in order to initiate post-exposure prophylaxis.
Source
Ayizo Biologics. Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products. Accessed July 17, 2023.
Comments ()